New Zealand markets closed
  • NZX 50

    11,580.81
    -14.13 (-0.12%)
     
  • NZD/USD

    0.6205
    -0.0049 (-0.78%)
     
  • NZD/EUR

    0.5760
    -0.0006 (-0.11%)
     
  • ALL ORDS

    7,137.60
    -11.00 (-0.15%)
     
  • ASX 200

    6,955.20
    -13.40 (-0.19%)
     
  • OIL

    69.20
    -0.76 (-1.09%)
     
  • GOLD

    1,981.00
    -14.90 (-0.75%)
     
  • NASDAQ

    12,767.05
    +37.82 (+0.30%)
     
  • FTSE

    7,405.45
    -94.15 (-1.26%)
     
  • Dow Jones

    32,237.53
    +132.28 (+0.41%)
     
  • DAX

    14,957.23
    -253.16 (-1.66%)
     
  • Hang Seng

    19,915.68
    -133.96 (-0.67%)
     
  • NIKKEI 225

    27,385.25
    -34.36 (-0.13%)
     
  • NZD/JPY

    81.0810
    -0.6720 (-0.82%)
     

Novo Nordisk files annual report with the SEC

Novo Nordisk A/S
Novo Nordisk A/S

Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022 on Form 20-F for the financial year 2022 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2022. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com.

Shareholders may receive a hardcopy of Novo Nordisk’s completed audited financial statements free of charge upon request to ancx@novonordisk.com.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube

Contact for further information

Media:

 

Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

Investors:

 

Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com


Attachment